Biopharmaceutical company ANI Pharmaceuticals Inc (Nasdaq:ANIP) said on Tuesday that it has completed the buyout of its 3.125% perpetual royalty obligation to SWK Funding LLC (SWK) on worldwide net revenues from ILUVIEN and YUTIQ.
The one-time payment of USD17.25m eliminates the royalty obligation, effective from 1 January 2025.
The buyout was funded using ANI's cash on hand. This transaction is part of ANI's strategy to strengthen its Retina portfolio and maximise the long-term value of ILUVIEN and YUTIQ.
Nikhil Lalwani, president and CEO of ANI, emphasized that this move enhances the company's financial flexibility and supports its goal of accelerating growth and improving patient outcomes.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government